Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
08/04/2022* -- Results Q2 2022 -- -0.43 --
08/04/2022* 08:30 EST Earnings Call Q2 2022 -- -- --
05/04/2022 -- Results Q1 2022 -0.44 -0.49 10.20%
05/04/2022 08:30 EST Earnings Call Q1 2022 -- -- --
02/23/2022 -- Results Q4 2021 -0.48 -0.50 3.36%
02/23/2022 08:30 EST Earnings Call Q4 2021 -- -- --
11/03/2021 -- Results Q3 2021 -0.56 -0.49 -14.29%
11/03/2021 08:30 EST Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 08/04/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 05/04/2022
Beat/Miss Upgrade
Return Since 1.19%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.
URL https://www.clovisoncology.com
Investor Relations URL https://ir.clovisoncology.com
HQ State/Province Colorado
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Aug. 04, 2022 (est.)
Last Earnings Release May. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-37.50%
26.91%
53.08%
-73.59%
-41.95%
-53.96%
-43.54%
-37.27%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.31%
5.92%
-41.45%
103.4%
10.58%
32.13%
7.94%
-7.08%
33.22%
--
--
--
--
--
--
--
-83.89%
0.31%
-22.77%
5.16%
7.48%
11.75%
-6.41%
-46.18%
28.98%
-54.98%
-74.71%
-69.44%
-67.17%
15.41%
63.41%
49.25%
-35.50%
As of June 24, 2022.

Profile

Edit
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.
URL https://www.clovisoncology.com
Investor Relations URL https://ir.clovisoncology.com
HQ State/Province Colorado
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Aug. 04, 2022 (est.)
Last Earnings Release May. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter CLVS Tweets